Skip to contentS
Supernus Pharmaceuticals, Inc.
S
SUPNSupernus Pharmaceuticals, Inc. Q2 2022 · 10-Q
Revenue$170.05M$170.05M+20.3% vs Q2 2021 Net Income$7.87M$7.87M−66.9% vs Q2 2021 EPS Diluted$0.14$0.14−67.4% vs Q2 2021 Operating Income$11,346,000−66.7% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Supernus Pharmaceuticals, Inc. · CIK 1356576 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$71,695,000+54.9% Margins · derivedOperating margin6.7%−17.5 pt vs Q2 2021
Net margin4.6%−12.2 pt vs Q2 2021
ended Jun 30, 2022 · filed Aug 8, 2022 · 39 d after period end